Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits, opposed by CDK inhibitors (CKIs) and checkpoint proteins. The G1/S restriction point — the irreversible commitment to cell division — is the most universally targeted cellular decision in oncogenesis, disrupted in virtually every human cancer through one of several alternative mechanisms: CDK4 amplification, cyclin D1 overexpression, p16INK4a (CDKN2A) deletion, or RB1 loss. Understanding this pathway reveals why CDK4/6 inhibitors work and which biomarkers predict resistance.
During G1, anti-mitogenic signals maintain pRb in its hypophosphorylated, E2F-repressing state. Mitogenic signals (RAS, WNT, PI3K) induce cyclin D1 accumulation, which assembles with CDK4/CDK6 and is T-loop activated by CAK. CDK4/6–cyclin D initially phosphorylates pRb at Ser780, partially de-repressing E2F targets including cyclin E. CDK2–cyclin E then hyperphosphorylates pRb, completing E2F release and constituting the restriction point crossover. This bistable switch ensures division commitment is irreversible once crossed.
During G1, anti-mitogenic signals maintain pRb in its hypophosphorylated, E2F-repressing state. Mitogenic signals (RAS, WNT, PI3K) induce cyclin D1 accumulation, which assembles with CDK4/CDK6 and is T-loop activated by CAK. CDK4/6–cyclin D initially phosphorylates pRb at Ser780, partially de-repressing E2F targets including cyclin E. CDK2–cyclin E then hyperphosphorylates pRb, completing E2F release and constituting the restriction point crossover. This bistable switch ensures division commitment is irreversible once crossed.
Cell Cycle G1→S Transition
Cyclin D1 binds CDK4 or CDK6, partially activating the kinase. CAK (CDK7–cyclin H) phosphorylates CDK4 at Thr172 for full kinase activation. p21 and p27 act as assembly factors at this stage, not inhibitors.
Newly synthesised CDK2–cyclin E hyperphosphorylates pRb at Ser795/811/821, completely releasing all bound E2F transcription factors. This creates a positive feedback loop (E2F drives more cyclin E, more CDK2 activity, more pRb phosphorylation) that makes the commitment irreversible — the restriction point.
Released E2F1/2/3 transcriptionally activate the complete S-phase programme: cyclin A, PCNA, MCM2-7 helicase complex, RRM1/2, and DNA polymerase δ components. CDK2–cyclin A replaces CDK2–cyclin E to drive S-phase progression.
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are the most successful targeted therapies for HR+/HER2− breast cancer, extending median progression-free survival by >12 months in pivotal trials. However, resistance invariably develops via RB1 loss (~25% of cases), CDK4/6 overexpression, or non-CDK4/6-dependent cell cycle re-entry. The pRb pathway is disrupted in virtually every cancer — by CDK4 amplification (liposarcoma), cyclin D1 overexpression (mantle cell lymphoma, breast), CDKN2A deletion (melanoma, pancreatic), or RB1 loss (SCLC, retinoblastoma).
CDK4/6 inhibitors are the paradigm of cell cycle-targeted therapy and require an intact RB1 gene for efficacy. Abemaciclib has additional CDK2/CDK9 activity and may retain partial activity in some RB1-intact tumours with non-classic resistance. Emerging approaches include CDK2 inhibitors (targeting cyclin E–CDK2 after CDK4/6 inhibitor resistance) and tri-complex CDK inhibitors targeting CDK4/cyclin D specifically over other CDKs.
Why does RB1 loss cause resistance to CDK4/6 inhibitors?
CDK4/6 inhibitors work by keeping pRb hypophosphorylated and E2F-bound, maintaining G1 arrest. If RB1 is deleted or mutated, there is no pRb for the drug to protect. Cells proceed through G1 and enter S phase regardless of CDK4/6 kinase status, rendering the inhibitors completely ineffective.
What is the restriction point and why is it cancer-relevant?
The restriction point is the G1 moment of irreversible commitment to cell division, defined by pRb hyperphosphorylation and complete E2F release. Before the restriction point, cells require sustained mitogenic signals; after it, they divide autonomously. Cancer cells bypass the restriction point constitutively through CDK4 amplification, cyclin D overexpression, CDKN2A loss, or RB1 inactivation.
How does p53 enforce the G1 checkpoint?
After DNA damage, ATM/CHK2-mediated p53 phosphorylation stabilises p53, which transcriptionally activates CDKN1A (encoding p21). p21 inhibits CDK2/cyclin E and CDK4/cyclin D complexes, preventing pRb phosphorylation and maintaining G1 arrest. This gives the cell time for DNA repair before committing to S phase — when replication would amplify any mutations.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway is the most frequently activated oncogenic signalling axis in human cancer, altered in over 70…
RAS/MAPK Signalling Pathway
The RAS/RAF/MEK/ERK (MAPK) cascade is one of the most ancient and conserved proliferative signalling pathways in eukaryo…
Content is based on peer-reviewed scientific literature including data from NCBI, UniProt, PubMed, and TCGA. Gene links reference curated molecular biology databases. For educational purposes only; does not constitute clinical advice.